• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Elucidation and control of immunosuppressive mechanisms by oncogenes and abnormal lipid metabolism in the tumor microenvironment

Research Project

Project/Area Number 20H03534
Research Category

Grant-in-Aid for Scientific Research (B)

Allocation TypeSingle-year Grants
Section一般
Review Section Basic Section 50020:Tumor diagnostics and therapeutics-related
Research InstitutionInternational University of Health and Welfare (2021-2022)
Keio University (2020)

Principal Investigator

Kawakami Yutaka  国際医療福祉大学, 医学部, 教授 (50161287)

Co-Investigator(Kenkyū-buntansha) 久保 亜紀子  慶應義塾大学, 医学部(信濃町), 助教 (50455573)
潮見 隆之  国際医療福祉大学, 医学部, 教授 (80348797)
Project Period (FY) 2020-04-01 – 2023-03-31
Project Status Completed (Fiscal Year 2022)
Budget Amount *help
¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000)
Fiscal Year 2022: ¥6,890,000 (Direct Cost: ¥5,300,000、Indirect Cost: ¥1,590,000)
Fiscal Year 2021: ¥6,890,000 (Direct Cost: ¥5,300,000、Indirect Cost: ¥1,590,000)
Fiscal Year 2020: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Keywordsがん微小環境 / がん遺伝子 / 脂質代謝 / 免疫抑制 / 免疫チェックポイント阻害薬
Outline of Research at the Start

本研究では、研究代表者の今までの成果に基づき、臨床検体やマウス腫瘍モデルを用いて、がん遺伝子異常と脂質代謝異常とがん免疫応答の関係を解析し、その細胞分子機構を解明するとともに、制御法を開発することにより、免疫チェックポイント阻害薬などのがん治療におけるバイオマーカーの同定やPD-1/PD-L1阻害を基軸とした効果的な複合がん免疫療法の開発のための基盤を作ることを目指す。

Outline of Final Research Achievements

In this study, we found that SCD1, a fatty acid metabolizing enzyme, is expressed in cancer cells and immune cells including T cells, and suppresses anti-tumor immune responses. In cancer cells, SCD1 reduced chemokine production partly through β-catenin signaling, resulting in suppression of tumor infiltration of dendritic cells and subsequent T cell induction. SCD1 also impaired T cell function directly via increasing ER stress. Administration of SCD1 inhibitors to mouse tumor models enhanced the induction and tumor infiltration of dendritic cells and anti-tumor CD8+ T cells, and its combined use with anti-PD-1 antibody enhanced the therapeutic effect. In lung cancer patients treated with anti-PD-1 antibody, serum SCD1-related fatty acids at baseline were correlated with response rate and prognosis. Therefore, SCD1 is one of the immunoresistance mechanisms, and a potential diagnostic and therapeutic target for cancer immunotherapy.

Academic Significance and Societal Importance of the Research Achievements

二人に一人ががんになる時代となり、がん治療のさらなる改善が期待されている。がん免疫療法、特に免疫チェックポイント阻害薬は、すでに標準的がん治療となったが、治療効果はまだ限定的であり、免疫抵抗性機序の解明とその改善によるがん免疫療法の改良が世界中で試みられている。本研究では、脂肪酸代謝酵素SCD1が免疫チェックポイント阻害薬の抵抗性機序になること、またその細胞・分子機構をマウス腫瘍モデルとヒトがん症例で明らかにした。本研究成果は、腫瘍免疫学の進歩だけでなく、免疫チェックポイント阻害薬とSCD1阻害薬を併用する複合がん免疫療法開発につながると期待される。

Report

(4 results)
  • 2022 Annual Research Report   Final Research Report ( PDF )
  • 2021 Annual Research Report
  • 2020 Annual Research Report
  • Research Products

    (71 results)

All 2023 2022 2021 2020

All Journal Article (35 results) (of which Int'l Joint Research: 5 results,  Peer Reviewed: 20 results,  Open Access: 18 results) Presentation (31 results) (of which Int'l Joint Research: 4 results,  Invited: 27 results) Book (5 results)

  • [Journal Article] Multicenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer2023

    • Author(s)
      Bernhard Mlecnik, Yutaka Kawakami(86/91)
    • Journal Title

      Cancers

      Volume: 15 Issue: 2 Pages: 418-437

    • DOI

      10.3390/cancers15020418

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] RTP4 silencing provokes tumor-intrinsic resistance to immune checkpoint blockade in colorectal cancer2023

    • Author(s)
      Yamamoto Yudai、Shimada Shu、Akiyama Yoshimitsu、Tsukihara Shu、Sugimoto Raizo、Kabashima Ayano、Tokunaga Masanori、Kinugasa Yusuke、Kawakami Yutaka、Tanaka Shinji
    • Journal Title

      Journal of Gastroenterology

      Volume: ND Issue: 6 Pages: 1-14

    • DOI

      10.1007/s00535-023-01969-w

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] 特集 がんの免疫療法 特別寄稿 がん免疫療法開発の現状と展望2023

    • Author(s)
      河上 裕
    • Journal Title

      ライフライン21 がんの先進医療

      Volume: 48 Pages: 14-15

    • Related Report
      2022 Annual Research Report
  • [Journal Article] Inhibition of stearoyl-CoA desaturase 1 (SCD1) enhances the antitumor T cell response through regulating β-catenin signaling in cancer cells and ER stress in T cells and synergizes with anti-PD-1 antibody2022

    • Author(s)
      Yuki Katoh, Tomonori Yaguchi, Akiko Kubo, Takashi Iwata, Kenji Morii, Daiki Kato, Shigeki Ohta, Ryosuke Satomi, Yasuhiro Yamamoto, Yoshitaka Oyamada, Kota Ouchi, Shin Takahashi, Chikashi Ishioka, Ryo Matoba, Makoto Suematsu, Yutaka Kawakami
    • Journal Title

      J Immunotherapy Cancer

      Volume: 10(7) Issue: 7 Pages: e004616-e004616

    • DOI

      10.1136/jitc-2022-004616

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study2022

    • Author(s)
      Mlecnik B, Torigoe T, Bindea G, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Kiyotaka O, Sato N, Furuhata T, Takemasa I, Patel P, Vora H, Shah B, Patel J, Rajvik K, Pandya S, Shukla S, Wang Y, Zhang G, Yoshino T
    • Journal Title

      Cancers

      Volume: 14 Issue: 18 Pages: 4346-4365

    • DOI

      10.3390/cancers14184346

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] TPT1 Supports Proliferation of Neural Stem/Progenitor Cells and Brain Tumor Initiating Cells Regulated by Macrophage Migration Inhibitory Factor (MIF)2022

    • Author(s)
      Morimoto y, Tokumitsu A, . , Shigeki Ohta
    • Journal Title

      Neurochem Res.

      Volume: 47(9) Issue: 9 Pages: 2741-2756

    • DOI

      10.1007/s11064-022-03629-6

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] CD4 and FOXP3 as predictive markers for the recurrence of T3/T4a stage II colorectal cancer: applying a novel discrete Bayes decision rule2022

    • Author(s)
      Nakagami Yuki、Hazama Shoichi、Suzuki Nobuaki、Yoshida Shin、Tomochika Shinobu、et al
    • Journal Title

      BMC Cancer

      Volume: 22 Issue: 1 Pages: 1071-1071

    • DOI

      10.1186/s12885-022-10181-7

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Melanoma antigens recognized by T cells and their use for immunotherapy2022

    • Author(s)
      Shigeki Ohta, Aya Misawa, Chaw Kyi-Tha-Thu, Naomi Matsumoto, Yoshie Hirose, Yutaka Kawakami
    • Journal Title

      Exp Dermatol

      Volume: 32(3) Issue: 3 Pages: 297-305

    • DOI

      10.1111/exd.14741

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] 総論 がん免疫療法の診断と治療の現状と展望:がん免疫療法開発の現状と展望2022

    • Author(s)
      河上 裕
    • Journal Title

      Vita

      Volume: 40 Pages: 24-28

    • Related Report
      2022 Annual Research Report
  • [Journal Article] Guidelines for clinical evaluation of anti‐cancer drugs2021

    • Author(s)
      Minami Hironobu、Kiyota Naomi、Kimbara Shiro、Ando Yuichi、Shimokata Tomoya、Ohtsu Atsushi、Fuse Nozomu、Kuboki Yasutoshi、Shimizu Toshio、Yamamoto Noboru、Nishio Kazuto、Kawakami Yutaka、Nihira Shin‐ichi、Sase Kazuhiro、Nonaka Takahiro、Takahashi Hideaki、Komori Yukiko、Kiyohara Koshin
    • Journal Title

      Cancer Science

      Volume: 112 Issue: 7 Pages: 2563-2577

    • DOI

      10.1111/cas.14967

    • NAID

      120007169038

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Multicenter Phase I/II Study of Nivolumab Combined with Paclitaxel Plus Ramucirumab as Second-line Treatment in Patients with Advanced Gastric Cancer2021

    • Author(s)
      Nakajima Takako Eguchi、Kadowaki Shigenori、Minashi Keiko、Nishina Tomohiro、Yamanaka Takeharu、Hayashi Yuichiro、Izawa Naoki、Muro Kei、Hironaka Shuichi、Kajiwara Takeshi、Kawakami Yutaka
    • Journal Title

      Clinical Cancer Research

      Volume: 27 Issue: 4 Pages: 1029-1036

    • DOI

      10.1158/1078-0432.ccr-20-3559

    • Related Report
      2021 Annual Research Report 2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Inhibition of vascular adhesion protein-1 enhances the anti-tumor effects of immune checkpoint inhibitors2021

    • Author(s)
      Kinoshita T, Sayem MA, Yaguchi T, Kharma B, Morii K, Kato D, Ohta S, Mashima Y, Asamura H, Kawakami Y
    • Journal Title

      Cancer Science

      Volume: 112 Issue: 4 Pages: 1390-1401

    • DOI

      10.1111/cas.14812

    • Related Report
      2021 Annual Research Report 2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Prospective observational study of the efficacy of nivolumab in Japanese patients with advanced melanoma (CREATIVE study)2021

    • Author(s)
      Yamazaki Naoya、Takenouchi Tatsuya、Nakamura Yasuhiro、Takahashi Akira、Namikawa Kenjiro、Kitano Shigehisa、Fujita Tomonobu、Kubota Kazumi、Yamanaka Takeharu、Kawakami Yutaka
    • Journal Title

      Japanese Journal of Clinical Oncology

      Volume: 51 Issue: 8 Pages: 1232-1241

    • DOI

      10.1093/jjco/hyab064

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Adoptive cell therapy using tumor-infiltrating lymphocytes for melanoma refractory to immune-checkpoint inhibitors.2021

    • Author(s)
      Hirai I, Funakoshi T, Kamijuku H, Fukuda K, Mori M, Sakurai M, Koda Y, Kato J, Mori T, Watanabe N, Noji S, Yaguchi T, Iwata T, Ohta S, Fujita T, Tanosaki R, Handa M, Okamoto S, Amagai M, Kawakami Y.
    • Journal Title

      Cancer Sci.

      Volume: 112 Issue: 8 Pages: 3163-3172

    • DOI

      10.1111/cas.15009

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] AIM2 regulates anti-tumor immunity and is a viable therapeutic target for melanoma2021

    • Author(s)
      Fukuda Keitaro、Okamura Ken、Riding Rebecca L.、Fan Xueli、Afshari Khashayar、Haddadi Nazgol-Sadat、McCauley Sean M.、Guney Mehmet H.、Luban Jeremy、Funakoshi Takeru、Yaguchi Tomonori、Kawakami Yutaka、Khvorova Anastasia、Fitzgerald Katherine A.、Harris John E.
    • Journal Title

      Journal of Experimental Medicine

      Volume: 218 Issue: 9

    • DOI

      10.1084/jem.20200962

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] CART療法への期待:歴史と課題2021

    • Author(s)
      河上 裕
    • Journal Title

      BioClinica

      Volume: 35

    • Related Report
      2021 Annual Research Report
  • [Journal Article] がん免疫療法とは何か2021

    • Author(s)
      河上 裕
    • Journal Title

      Newton

      Volume: 別冊 Pages: 156-165

    • Related Report
      2021 Annual Research Report
  • [Journal Article] がん・造血器腫瘍に対する免疫療法の新展開2021

    • Author(s)
      河上 裕
    • Journal Title

      日本検査血液学会雑誌

      Volume: 23 Pages: 1-8

    • Related Report
      2021 Annual Research Report
  • [Journal Article] 悪性黒色腫の分子生物学の進歩とその臨床応用2021

    • Author(s)
      河上 裕
    • Journal Title

      日本臨牀

      Volume: 79 Pages: 78-80

    • Related Report
      2021 Annual Research Report
  • [Journal Article] 悪性黒色腫の免疫病態2021

    • Author(s)
      河上 裕
    • Journal Title

      日本臨牀

      Volume: 79 Pages: 124-131

    • Related Report
      2021 Annual Research Report
  • [Journal Article] 腫瘍抗原2021

    • Author(s)
      河上 裕
    • Journal Title

      呼吸器ジャーナル

      Volume: 68 Pages: 342-345

    • Related Report
      2021 Annual Research Report
  • [Journal Article] がん免疫研究とがん免疫療法の展望2021

    • Author(s)
      河上 裕
    • Journal Title

      医学のあゆみ

      Volume: 275 Pages: 432-439

    • Related Report
      2021 Annual Research Report
  • [Journal Article] 個別化・複合がん免疫療法の開発に向けて2021

    • Author(s)
      河上 裕
    • Journal Title

      PULMOMICS

      Volume: 創刊号 Pages: 8-11

    • Related Report
      2021 Annual Research Report
  • [Journal Article] がん微小環境2021

    • Author(s)
      河上 裕
    • Journal Title

      TRENDS IN CANCER IMMUNOLOGY

      Volume: 4 Pages: 6-11

    • Related Report
      2021 Annual Research Report
  • [Journal Article] がん微小環境における免疫代謝異常2021

    • Author(s)
      河上 裕
    • Journal Title

      TRENDS IN CANCER IMMUNOLOGY

      Volume: 4 Pages: 6-11

    • Related Report
      2021 Annual Research Report
  • [Journal Article] Siglec-7 is a predictive biomarker for the efficacy of cancer vaccination against metastatic colorectal cancer2020

    • Author(s)
      Yamada Kensuke、Hazama Shoichi、Suzuki Nobuaki、Xu Ming、Nakagami Yuki、Fujiwara Nobuyuki、Tsunedomi Ryouichi、Yoshida Shin、Tomochika Shinobu、Matsukuma Satoshi、Matsui Hiroto、Tokumitsu Yukio、Kanekiyo Shinsuke、Shindo Yoshitaro、Watanabe Yusaku、Iida Michihisa、Takeda Shigeru、Ioka Tatsuya、Ueno Tomio、et al.
    • Journal Title

      Oncology Letters

      Volume: 21 Issue: 1 Pages: 1-1

    • DOI

      10.3892/ol.2020.12271

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Enhanced anti-tumor effects of the PD-1 blockade combined with a highly absorptive form of curcumin targeting STAT32020

    • Author(s)
      Hayakawa T, Yaguchi T, Kawakami Y
    • Journal Title

      Cancer Science

      Volume: 111 Issue: 12 Pages: 4626-4635

    • DOI

      10.1111/cas.14675

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer2020

    • Author(s)
      Mlecnik B., Kawakami Y, Galon J
    • Journal Title

      Journal of Clinical Oncology

      Volume: 38 Issue: 31 Pages: 3638-3651

    • DOI

      10.1200/jco.19.03205

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Int'l Joint Research
  • [Journal Article] Tumor-infiltrating lymphocytes predict survival outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy2020

    • Author(s)
      Akiko Ohno, Takashi Iwata, Yuki Katoh, Shiho Taniguchi, Kohsei Tanaka, Hiroshi Nishio, Masaru Nakamura , Tohru Morisada, Guanliang Chen, Miyuki Saito, Tomonori Yaguchi, Yutaka Kawakami, Daisuke Aoki
    • Journal Title

      Gynecol Oncol .

      Volume: 159 Issue: 2 Pages: 329-334

    • DOI

      10.1016/j.ygyno.2020.07.106

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Interface of cancer stem cells and cancer immunity2020

    • Author(s)
      Kinoshita T, Kawakami Y
    • Journal Title

      Annals of Translational Medicine

      Volume: 8 Issue: 13 Pages: 810-812

    • DOI

      10.21037/atm.2020.04.08

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Immune-resistant mechanisms in cancer immunotherapy2020

    • Author(s)
      Kawakami Y, Ohta S, Sayem MA, Tsukamoto N, Yaguchi T.
    • Journal Title

      Int J Clin Oncol.

      Volume: 25 Issue: 5 Pages: 810-817

    • DOI

      10.1007/s10147-019-01611-x

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series2020

    • Author(s)
      Tamura R, Morimoto Y, Kosugi K, Sato M, Oishi Y, Ueda R, Kikuchi R, Nagashima H, Hikichi T, Noji S, Kawakami Y, Sasaki H, Yoshida K, Toda M
    • Journal Title

      BMC Cancer

      Volume: 20 Issue: 1 Pages: 196-205

    • DOI

      10.1186/s12885-020-6589-x

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] 【進行期肺癌治癒への道-がんゲノム医療と免疫プレシジョン医療の接点-】総論 腫瘍抗原2020

    • Author(s)
      河上 裕
    • Journal Title

      呼吸器ジャーナル

      Volume: 68 Pages: 342-345

    • Related Report
      2020 Annual Research Report
  • [Journal Article] がん免疫療法2020

    • Author(s)
      河上 裕
    • Journal Title

      テクノロジー・ロードマップ2021-2030  医療・健康・食農編(2021-2030)

      Volume: -

    • Related Report
      2020 Annual Research Report
  • [Journal Article] がん免疫研究とがん免疫療法の展望 固形腫瘍の網羅的なゲノム解析と分子標的2020

    • Author(s)
      河上 裕
    • Journal Title

      医学のあゆみ

      Volume: 275 Pages: 432-439

    • Related Report
      2020 Annual Research Report
  • [Presentation] がんと免疫の相互作用の理解と免疫療法の開発:歴史と未来2023

    • Author(s)
      河上 裕
    • Organizer
      第16回NPO健康医療開発機構シンポジウム
    • Related Report
      2022 Annual Research Report
    • Invited
  • [Presentation] Cancer immunotherapies2022

    • Author(s)
      河上 裕
    • Organizer
      The 1st International Symposium of Clinical Immunology
    • Related Report
      2022 Annual Research Report
    • Invited
  • [Presentation] Development of Combination Immunotherapy Based on the Immunological Subtyping of Cancer2022

    • Author(s)
      河上 裕
    • Organizer
      9th US-JAPAN CONFERENCE ON ONCOLOGY
    • Related Report
      2022 Annual Research Report
    • Int'l Joint Research / Invited
  • [Presentation] がん免疫療法の最近の進歩:個別化・複合がん免疫療法の開発に向けて2022

    • Author(s)
      河上 裕
    • Organizer
      第21回関西肝血流動態・機能イメージ研究会
    • Related Report
      2022 Annual Research Report
    • Invited
  • [Presentation] Immersion in the understanding of cancer immunology2022

    • Author(s)
      河上 裕
    • Organizer
      第26回日本がん免疫学会総会
    • Related Report
      2022 Annual Research Report
    • Invited
  • [Presentation] 腫瘍免疫学とがん免疫療法の最近の進歩2022

    • Author(s)
      河上 裕
    • Organizer
      第2回HCC Basic Research Web Conference
    • Related Report
      2022 Annual Research Report
    • Invited
  • [Presentation] Recent advances in cancer immunology and immunotherapy using new technologies2022

    • Author(s)
      河上 裕
    • Organizer
      第81回 日本癌学会学術総会
    • Related Report
      2022 Annual Research Report
    • Invited
  • [Presentation] Advances in human cancer immunology and immunotherapy:Potential use of humanized mouse models2022

    • Author(s)
      河上 裕
    • Organizer
      6th International Workshop on Humanized Mice (IWHM VI)
    • Related Report
      2022 Annual Research Report
    • Int'l Joint Research / Invited
  • [Presentation] Combination immunotherapy trageting stearoyl-CoA desaturase 1 (SCD1) with immunosuppressive activity2022

    • Author(s)
      Yuki Katoh, Tomonori Yaguchi , Akiko Kubo ,Takashi Iwata , Kenji Morii , Daiki Kato, Shigeki Ohta , Makoto Suematsu , Yutaka Kawakami
    • Organizer
      第51回 日本免疫学術総会
    • Related Report
      2022 Annual Research Report
  • [Presentation] ヒトがん免疫応答解析に向けたヒト化マウスの開発2021

    • Author(s)
      河上 裕
    • Organizer
      第68回日本実験動物学会総会
    • Related Report
      2021 Annual Research Report
    • Invited
  • [Presentation] 効果的な複合がん免疫療法に向けた免疫制御法の開発2021

    • Author(s)
      河上 裕
    • Organizer
      第85回日本インターフェロン・サイトカイン学会学術集会
    • Related Report
      2021 Annual Research Report
    • Invited
  • [Presentation] がん免疫研究を介した効果的ながん免疫療法の開発に向けて2021

    • Author(s)
      河上 裕
    • Organizer
      第13回日本血液疾患免疫療法学会学術集会
    • Related Report
      2021 Annual Research Report
    • Invited
  • [Presentation] がん免疫研究・がん免疫療法の最新研究:リンパ球など免疫バイオマーカー2021

    • Author(s)
      河上 裕
    • Organizer
      日本肉腫学会
    • Related Report
      2021 Annual Research Report
    • Invited
  • [Presentation] がん・造血器腫瘍に対する免疫療法の新展開2021

    • Author(s)
      河上 裕
    • Organizer
      第22回日本検査血液学会学術集会
    • Related Report
      2021 Annual Research Report
    • Invited
  • [Presentation] がんと免疫:認識・逃避・排除2021

    • Author(s)
      河上 裕
    • Organizer
      第49回日本臨床免疫学会総会
    • Related Report
      2021 Annual Research Report
    • Invited
  • [Presentation] がん免疫病態の統合的な理解個別化 複合がん免疫療法の開発に向けて2021

    • Author(s)
      河上 裕
    • Organizer
      AIR-Angiogenesis&Immunology Research-研究会
    • Related Report
      2021 Annual Research Report
    • Invited
  • [Presentation] がん免疫療法の進歩2021

    • Author(s)
      河上 裕
    • Organizer
      第19回日本臨床腫瘍学会学術集会
    • Related Report
      2021 Annual Research Report
    • Invited
  • [Presentation] Cancer Immunotherapy:The Past, Present & Future2021

    • Author(s)
      河上 裕
    • Organizer
      シンガポール・マレーシアOncology Keynote lecture
    • Related Report
      2021 Annual Research Report
    • Int'l Joint Research / Invited
  • [Presentation] より効果的ながん免疫療法の開発を目指して2021

    • Author(s)
      河上 裕
    • Organizer
      Japan Cancer Forum2021 市民公開講座
    • Related Report
      2021 Annual Research Report
    • Invited
  • [Presentation] がん微小環境における脂質代謝の制御は、抗腫瘍免疫応答を増強し、抗PD-1抗体の効果を増強する2021

    • Author(s)
      加藤 侑希、谷口 智憲、岩田 卓、川名 敬 、河上 裕
    • Organizer
      第36回日本生殖免疫学会総会・学術集会
    • Related Report
      2021 Annual Research Report
  • [Presentation] A phase I/II study of nivolumab, paclitaxel and ramucirumab as 2nd-line in advanced gastric cancer2021

    • Author(s)
      河上 裕
    • Organizer
      第92回日本胃癌学会総会
    • Related Report
      2020 Annual Research Report
    • Invited
  • [Presentation] 個別化複合がん免疫療法の開発に向けて, シンポジウムがん免疫と分子標的治療2021

    • Author(s)
      河上 裕
    • Organizer
      第23回日本肝がん分子標的治療研究会
    • Related Report
      2020 Annual Research Report
    • Invited
  • [Presentation] Potential biomarkers for immunotherapy of gastric cancer, シンポジウム:切除不能・再発胃がんに対する免疫療法の現状と展望2021

    • Author(s)
      河上 裕
    • Organizer
      第18回日本臨床腫瘍学会学術集会
    • Related Report
      2020 Annual Research Report
    • Invited
  • [Presentation] 個別化・複合がん免疫療法の開発に向けて 抗腫瘍免疫と免疫抵抗性の機序2021

    • Author(s)
      河上 裕
    • Organizer
      第18回日本臨床腫瘍学会学術集会
    • Related Report
      2020 Annual Research Report
    • Invited
  • [Presentation] 腫瘍免疫学の最近の進歩: 個別化・複合がん免疫療法の開発に向けて2020

    • Author(s)
      河上 裕
    • Organizer
      AstraZeneca Scientific Exchange Meeting
    • Related Report
      2020 Annual Research Report
    • Invited
  • [Presentation] 免疫関連有害事象 悪性腫瘍における免疫療法とチェックポイント阻害薬: 最近の進歩とトピックス2020

    • Author(s)
      河上 裕
    • Organizer
      第64回日本リウマチ学会総会・学術集会
    • Related Report
      2020 Annual Research Report
    • Invited
  • [Presentation] A phase I/II study of nivolumab, paclitaxel and ramucirumab as 2nd-line in advanced gastric cancer Angiogenesis-related factors and clinical outcomes in combination therapy with paclitaxel (PTX), ramucirumab (RAM) plus nivolumab (Nivo) for advanced gastric cancer (AGC)2020

    • Author(s)
      Izawa N, Kawakami Y et al
    • Organizer
      ESMO Virtual Congress 2020
    • Related Report
      2020 Annual Research Report
    • Int'l Joint Research
  • [Presentation] Cancer immunology research toward development of personalized immunotherapy 個別化免疫療法開発に向けたがん免疫研究2020

    • Author(s)
      河上 裕
    • Organizer
      第79回日本癌学会学術総会
    • Related Report
      2020 Annual Research Report
    • Invited
  • [Presentation] Dynamics of CD8+ T cell subsets correlated with clinical response to anti-PD-1 antibody2020

    • Author(s)
      河上 裕
    • Organizer
      第79回日本癌学会学術総会
    • Related Report
      2020 Annual Research Report
    • Invited
  • [Presentation] Development of cancer immunotherapy through elucidation of human immune responses to cancer ヒトがん免疫応答の解明によるがん免疫療法の開発2020

    • Author(s)
      河上 裕
    • Organizer
      第79回日本癌学会学術総会 長與賞受賞講演
    • Related Report
      2020 Annual Research Report
    • Invited
  • [Presentation] Peripheral blood CD8+ T cell subsets identified by scRNA-seq correlate with PD-1 Ab response in lung cancer patients2020

    • Author(s)
      大多 茂樹、河上 裕
    • Organizer
      第79回日本癌学会学術総会
    • Related Report
      2020 Annual Research Report
  • [Book] テクノロジー・ロードマップ2023-2032「第2章 医療 3.がん免疫療法」2022

    • Author(s)
      河上 裕、他100名
    • Total Pages
      608
    • Publisher
      日経BP
    • Related Report
      2022 Annual Research Report
  • [Book] がん治療の現在2021

    • Author(s)
      永山 悦子
    • Total Pages
      288
    • Publisher
      ディスカバー・トゥエンティワン
    • Related Report
      2021 Annual Research Report
  • [Book] あなたにとって最適な「がん治療」がわかる本2021

    • Author(s)
      がん情報サイト「オンコロ」
    • Total Pages
      208
    • Publisher
      日本実業出版社
    • Related Report
      2021 Annual Research Report
  • [Book] テクノロジー・ロードマップ 2021-2030「第2章 医療 3.がん免疫療法」2021

    • Author(s)
      河上 裕、他85名
    • Total Pages
      392
    • Publisher
      日経BP
    • Related Report
      2021 Annual Research Report
  • [Book] 【Tumor Microenvironment 】Renin-Angiotensin System in the Tumor Microenvironment2020

    • Author(s)
      Nakamura K, Okuyama R, Kawakami Y
    • Total Pages
      162
    • Publisher
      Springer
    • ISBN
      9783030502232
    • Related Report
      2020 Annual Research Report

URL: 

Published: 2020-04-28   Modified: 2024-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi